VNDA

+ Watchlist + Portfolio

Vanda Pharmaceuticals Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $5.57
52-Week Range: $4.27 – $9.94
Market Cap: $325.29M
P/E (TTM): —
EPS (TTM): -4.64
Dividend Yield: —

Advanced Metrics

Price/Book: 1.15
PEG Ratio: 2.23
Return on Equity: -77.81%
Return on Assets: -22.38%
Gross Margin: 93.74%
Operating Margin: -126.28%
Profit Margin: -127.41%
Current Ratio: 1.61
Debt/Equity: 0.10
Total Debt: $22.83M
Free Cash Flow: $-86.72M
Revenue Growth: -3.90%
Earnings Growth: —
Enterprise Value: $178.09M

VNDA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$254.38M	$192.64M	$198.77M	$216.10M
Cost of Revenue	$24.28M	$14.80M	$11.31M	$13.04M
Gross Profit	$230.10M	$177.84M	$187.46M	$203.06M
Research & Development	$85.77M	$76.82M	$74.43M	$109.27M
Selling, General & Admin	$136.49M	$112.88M	$146.41M	$237.95M
Operating Expenses	$223.77M	$191.80M	$228.12M	$354.23M
Operating Income	$6.33M	-$13.95M	-$40.66M	-$151.17M
EBITDA	$9.06M	-$9.62M	-$30.86M	-$139.25M
Pretax Income	$11.30M	$6.34M	-$22.92M	-$138.65M
Income Tax	$5.03M	$3.83M	-$4.02M	$81.83M
Net Income	$6.28M	$2.51M	-$18.90M	-$220.47M
Diluted EPS	0.11	0.04	-0.33	-3.74
Diluted Shares	56.98M	57.56M	58.15M	58.93M

VNDA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$135.03M	$135.82M	$102.32M	$84.85M
Receivables	$33.51M	$34.16M	$47.10M	$54.58M
Inventory	$1.19M	$1.36M	$1.73M	$1.85M
Current Assets	$519.29M	$432.95M	$438.89M	$347.26M
Total Assets	$634.25M	$648.44M	$656.20M	$488.95M
Current Liabilities	$91.44M	$87.70M	$99.98M	$145.16M
Total Debt	$11.14M	$9.40M	$12.36M	$12.62M
Total Liabilities	$107.05M	$103.53M	$117.66M	$161.76M
Retained Earnings	-$157.90M	-$155.39M	-$174.29M	-$394.77M
Shareholders' Equity	$527.20M	$544.91M	$538.55M	$327.19M
Working Capital	$427.86M	$345.25M	$338.91M	$202.10M

VNDA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$31.98M	$12.80M	-$15.76M	-$109.44M
Capital Expenditure	-$679.00K	-$383.00K	-$490.00K	-$998.00K
Free Cash Flow	$31.30M	$12.42M	-$16.25M	-$110.44M
Depreciation & Amortisation	$2.73M	$4.33M	$9.80M	$11.92M
Stock-Based Compensation	$16.28M	$14.04M	$12.43M	$9.47M
Investing Cash Flow	$49.92M	-$12.06M	-$17.43M	$94.86M
Financing Cash Flow	$734.00K	$0.00	-$155.00K	-$2.91M
Net Change in Cash	$82.64M	$745.00K	-$33.34M	-$17.49M

VNDA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$50.04M	$52.59M	$56.26M	$57.22M	$51.72M
Cost of Revenue	$3.52M	$2.74M	$2.95M	$3.83M	$3.16M
Gross Profit	$46.52M	$49.85M	$53.30M	$53.38M	$48.56M
Research & Development	$35.71M	$21.99M	$22.56M	$29.01M	$28.43M
Selling, General & Admin	$50.08M	$64.62M	$60.27M	$62.98M	$68.36M
Operating Expenses	$87.55M	$88.36M	$84.59M	$93.74M	$98.78M
Operating Income	-$41.03M	-$38.50M	-$31.28M	-$40.35M	-$50.22M
EBITDA	-$38.20M	-$36.75M	-$29.23M	-$34.49M	-$46.70M
Pretax Income	-$37.37M	-$34.89M	-$28.39M	-$38.00M	-$48.42M
Income Tax	-$7.87M	-$7.68M	-$5.80M	$103.19M	$143.00K
Net Income	-$29.49M	-$27.21M	-$22.59M	-$141.19M	-$48.57M
Diluted EPS	-0.50	-0.46	-0.38	-2.39	-0.82
Diluted Shares	58.53M	58.99M	59.09M	59.10M	59.46M

VNDA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$111.80M	$80.98M	$70.02M	$84.85M	$54.03M
Receivables	$44.60M	$44.99M	$50.54M	$54.58M	$56.88M
Inventory	$1.92M	$2.17M	$2.04M	$1.85M	$1.70M
Current Assets	$407.91M	$394.92M	$367.50M	$347.26M	$293.17M
Total Assets	$631.94M	$624.75M	$601.14M	$488.95M	$433.52M
Current Liabilities	$103.92M	$121.49M	$117.87M	$145.16M	$135.58M
Total Debt	$11.74M	$11.64M	$10.91M	$12.62M	$13.07M
Total Liabilities	$120.52M	$138.42M	$135.14M	$161.76M	$152.76M
Retained Earnings	-$203.79M	-$230.99M	-$253.58M	-$394.77M	-$443.33M
Shareholders' Equity	$511.42M	$486.33M	$466.00M	$327.19M	$280.76M
Working Capital	$303.99M	$273.43M	$249.63M	$202.10M	$157.59M

VNDA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$33.15M	-$15.25M	-$31.63M	-$29.42M	-$50.22M
Capital Expenditure	-$436.00K	-$299.00K	-$161.00K	-$102.00K	-$10.22M
Free Cash Flow	-$33.58M	-$15.55M	-$31.79M	-$29.52M	-$60.44M
Depreciation & Amortisation	$2.83M	$1.17M	$2.05M	$5.86M	$3.53M
Stock-Based Compensation	$2.97M	$2.11M	$2.11M	$2.29M	$2.56M
Investing Cash Flow	$43.90M	-$15.27M	$21.36M	$44.87M	$20.23M
Financing Cash Flow	-$1.32M	-$425.00K	-$517.00K	-$640.00K	-$776.00K
Net Change in Cash	$9.43M	-$30.95M	-$10.78M	$14.81M	-$30.76M

Market Snapshot

About

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for central nervous system disorders. The company markets treatments for conditions including non-24-hour sleep-wake disorder and nighttime sleep disturbances in totally blind individuals.